209 related articles for article (PubMed ID: 35349618)
1. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
[TBL] [Abstract][Full Text] [Related]
2. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
Satoh TK; Neulinger MM; Stadler PC; Aoki R; French LE
J Dermatol; 2024 Jan; 51(1):3-11. PubMed ID: 38031902
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
Robinson S; Saleh J; Curry J; Mudaliar K
Am J Dermatopathol; 2020 Apr; 42(4):292-296. PubMed ID: 31567395
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
[TBL] [Abstract][Full Text] [Related]
6. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
Chen CB; Wang CW; Chung WH
Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
[TBL] [Abstract][Full Text] [Related]
7. Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Treated Successfully with Oral Cyclosporin: Case report and literature review.
Al Rajaibi R; Al Rumhi T; Al Abri AM
Sultan Qaboos Univ Med J; 2021 Aug; 21(3):491-494. PubMed ID: 34522420
[TBL] [Abstract][Full Text] [Related]
8. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
[TBL] [Abstract][Full Text] [Related]
9. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
10. Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report.
Zizi N; Elmrahi A; Dikhaye S; Fihmi N; Alami Z
Tunis Med; 2015 Jul; 93(7):413-5. PubMed ID: 26757493
[TBL] [Abstract][Full Text] [Related]
11. Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Case Report and Literature Review.
Meledathu S; Gordon M; Thornton M; Ashinoff R
J Drugs Dermatol; 2023 Nov; 22(11):e24-e28. PubMed ID: 37943271
[TBL] [Abstract][Full Text] [Related]
12. [Bullous drug reaction after pembrolizumab administration: two case reports].
Golle L; Michl C; Kreft B
Dermatologie (Heidelb); 2022 Dec; 73(12):959-964. PubMed ID: 35925211
[TBL] [Abstract][Full Text] [Related]
13. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
Maloney NJ; Ravi V; Cheng K; Bach DQ; Worswick S
Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
[TBL] [Abstract][Full Text] [Related]
14. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.
Worswick S; Cotliar J
Dermatol Ther; 2011; 24(2):207-18. PubMed ID: 21410610
[TBL] [Abstract][Full Text] [Related]
15. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.
Alexandris D; Alevizopoulos N; Gakiopoulou H; Stavrinou N; Vourlakou C
J Oncol Pharm Pract; 2022 Jul; 28(5):1276-1282. PubMed ID: 35038934
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study.
Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH
J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514
[TBL] [Abstract][Full Text] [Related]
18. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
Abe R
J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.
Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S
Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in a Vietnamese patient with nonsmall-cell lung cancer.
Pham YTH; Vu MT; Nguyen AQ; Trinh PN; Tran MH; Chu HC; Nguyen NTM; Vu CHV; Nguyen DV
Asia Pac Allergy; 2024 Jun; 14(2):84-89. PubMed ID: 38827262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
